157 related articles for article (PubMed ID: 31381964)
41. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
42. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
43. Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma.
Parrula C; Fernandez SA; Zimmerman B; Lairmore M; Niewiesk S
J Gen Virol; 2011 Jun; 92(Pt 6):1458-1466. PubMed ID: 21325484
[TBL] [Abstract][Full Text] [Related]
44. Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus.
Scheubeck G; Berchtold S; Smirnow I; Schenk A; Beil J; Lauer UM
Viruses; 2019 Jul; 11(7):. PubMed ID: 31284426
[TBL] [Abstract][Full Text] [Related]
45. Regulatory aspects of oncolytic virus products.
Yamaguchi T; Uchida E
Curr Cancer Drug Targets; 2007 Mar; 7(2):203-8. PubMed ID: 17346112
[TBL] [Abstract][Full Text] [Related]
46. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
47. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
49. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
[TBL] [Abstract][Full Text] [Related]
50. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
51. An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
Lal S; Carrera D; Phillips JJ; Weiss WA; Raffel C
Neuro Oncol; 2018 Nov; 20(12):1606-1615. PubMed ID: 29912438
[TBL] [Abstract][Full Text] [Related]
52. [Measles virus: a future therapeutic agent in oncology?].
Touchefeu Y; Schick U; Harrington KJ
Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
[TBL] [Abstract][Full Text] [Related]
53. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
54. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
55. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
56. Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.
Ashton LV; Quackenbush SL; Castle J; Wilson G; McCoy J; Jordan M; MacNeill AL
Viruses; 2020 May; 12(5):. PubMed ID: 32397134
[TBL] [Abstract][Full Text] [Related]
57. Development of Entry-Targeted Oncolytic Measles Viruses.
Mühlebach MD; Cattaneo R
Methods Mol Biol; 2020; 2058():51-75. PubMed ID: 31486031
[TBL] [Abstract][Full Text] [Related]
58. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Urbasic AS; Hynes S; Somrak A; Contakos S; Rahman MM; Liu J; MacNeill AL
Am J Vet Res; 2012 Aug; 73(8):1252-61. PubMed ID: 22849686
[TBL] [Abstract][Full Text] [Related]
59. Combination of Oncolytic Measles Virus and Ursolic Acid Synergistically Induces Oncolysis of Hepatocellular Carcinoma Cells.
Liu CH; Tai CJ; Kuo YT; Chang SS; Lin LT
Viruses; 2023 May; 15(6):. PubMed ID: 37376594
[TBL] [Abstract][Full Text] [Related]
60. Pro-oncogenic cell signaling machinery as a target for oncolytic viruses.
Borrego-Diaz E; Mathew R; Hawkinson D; Esfandyari T; Liu Z; Lee PW; Farassati F
Curr Pharm Biotechnol; 2012 Jul; 13(9):1742-9. PubMed ID: 21740363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
